Explore the words cloud of the VAC2VAC project. It provides you a very rough idea of what is the project "VAC2VAC" about.
The following table provides information about the project.
Coordinator |
EUROPEAN VACCINE INITIATIVE EWIV
Organization address contact info |
Coordinator Country | Germany [DE] |
Project website | http://www.vac2vac.eu |
Total cost | 16˙290˙929 € |
EC max contribution | 7˙850˙000 € (48%) |
Programme |
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2)) |
Code Call | H2020-JTI-IMI2-2015-03-two-stage |
Funding Scheme | IMI2-RIA |
Starting year | 2016 |
Duration (year-month-day) | from 2016-03-01 to 2021-02-28 |
Take a look of project's partnership.
Lot release testing of established vaccines relies on using animal models. Many of these models were developed decades ago and reflect the level of product knowledge, production technology and quality management in those days. Current production techniques are optimised, in-process control is implemented and tight quality management systems are in place. These developments have brought testing for lot-to-lot consistency into reach. The consistency approach involves the use of a set of parameters obtained by using innovative in vitro technologies, to define the product along the manufacturing pathway and to ensure similarity to a lot of proven efficacy and safety.
The ambition of the VAC2VAC project is a demonstrated proof of concept of the consistency approach for lot release testing. We will develop/optimise and validate innovative in vitro methods for the categories of established vaccines on the market. Product profiles will be defined using analytical methods, cell-based assays and bioinformatics.
The project includes 7 WPs: 4 on R&D, and one each on validation, promotion to regulatory acceptance and consortium management. Consortium partners represent the vaccine stakeholder groups (OMCLs, Academia, Translational research institutes and Vaccinology alliances) and are complementary for the expertise ranging from method development and validation to facilitating and providing guidance to regulatory acceptance. Acceptance will be promoted by strategic guidance activities: a roadmap conference, workshops and training courses. Implementation of the consistency approach in lot release testing has multiple impact: 1) strengthening fundamental understanding of vaccine products resulting in enhanced understanding of vaccine quality 2) strengthening competitiveness of European Vaccine Industries resulting in reduced QC costs and shortened QC time. 3) strengthening European animal welfare policies resulting in a substantial reduction in animal numbers for vaccine QC
Project meetings and conferences. | Other | 2020-03-24 16:36:20 |
Establishment of SEAC. | Other | 2020-03-24 16:36:20 |
Preparation of communication material including launch of project webpage. | Websites, patent fillings, videos etc. | 2020-03-24 16:36:20 |
Take a look to the deliverables list in detail: detailed list of VAC2VAC deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2018 |
Marlies Halder, Hilde Depraetere, Frédérique Delannois, Arnoud Akkermans, Marie-Emmanuelle Behr-Gross, Martijn Bruysters, Jean-François Dierick, Carmen Jungbäck, Imke Kross, Bernard Metz, Jeroen Pennings, Peter Rigsby, Patrice Riou, Elisabeth Balks, Alexandre Dobly, Odile Leroy, Catrina Stirling Recommendations of the VAC2VAC workshop on the design of multi-centre validation studies published pages: 78-82, ISSN: 1045-1056, DOI: 10.1016/j.biologicals.2018.01.003 |
Biologicals 52 | 2020-03-24 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VAC2VAC" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "VAC2VAC" are provided by the European Opendata Portal: CORDIS opendata.
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Read More